menu
    • menu
    [{"orgOrder":0,"company":"RxOMEG Therapeutics","sponsor":"Scilex Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Rheumatology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2022","type":"Licensing Agreement","leadProduct":"Colchicine","moa":"Beta-tubulin polymerisation","graph1":"Rheumatology","graph2":"Approved FDF","graph3":"RxOMEG Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"RxOMEG Therapeutics \/ Scilex Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"RxOMEG Therapeutics \/ Scilex Pharmaceuticals"},{"orgOrder":0,"company":"RxOMEG Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"RMG-03","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"RxOMEG Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RxOMEG Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"RxOMEG Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"RxOMEG Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Pilocarpine Hydrochloride","moa":"M1 receptor","graph1":"Dental and Oral Health","graph2":"Preclinical","graph3":"RxOMEG Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"RxOMEG Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"RxOMEG Therapeutics \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by RxOMEG Therapeutics

    Menu

    RxOMEG Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            RxOMEG Therapeutics

                            U.S.A arrow
                            German Wound Congress
                            Not Confirmed

                            RxOMEG Therapeutics

                            U.S.A arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RMG-03

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Romeg Therapeutics Announces Publication of RMG-03 Phase 2 Study Results in COVID-19

                            Details : RMG-03 shows beneficial effect in hyperinflammatory syndromes mediated by severe viral illnesses such as SARS-CoV-2. It has recently completed Phase 2 proof of concept study in COVID-19 patients.

                            Product Name : RMG-03

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            April 04, 2023

                            Lead Product(s) : RMG-03

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            RxOMEG Therapeutics

                            U.S.A arrow
                            German Wound Congress
                            Not Confirmed

                            RxOMEG Therapeutics

                            U.S.A arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pilocarpine Hydrochloride

                            Therapeutic Area : Dental and Oral Health

                            Study Phase : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Romeg Therapeutics Announces Issuance of U.S. Patent for Pilocarpine Oral Solution

                            Details : Pilocarpine is a muscarinic cholinergic agonist used on the eye to treat elevated intraocular pressure, various types of glaucoma, and to induce miosis. Also available orally to treat symptoms of dry mouth associated with Sjogren's syndrome and radiother...

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            January 02, 2023

                            Lead Product(s) : Pilocarpine Hydrochloride

                            Therapeutic Area : Dental and Oral Health

                            Highest Development Status : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            RxOMEG Therapeutics

                            U.S.A arrow
                            German Wound Congress
                            Not Confirmed

                            RxOMEG Therapeutics

                            U.S.A arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Colchicine

                            Therapeutic Area : Rheumatology

                            Study Phase : Approved FDF

                            Sponsor : Scilex Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Scilex Holding Company, a Sorrento Company, Enters Into an Agreement for An Exclusive License With ROMEG Thera...

                            Details : Gloperba is the first liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults and was made available in the United States in 2020.

                            Product Name : Gloperba

                            Product Type : Plant Extract/Herbal

                            Upfront Cash : Undisclosed

                            June 14, 2022

                            Lead Product(s) : Colchicine

                            Therapeutic Area : Rheumatology

                            Highest Development Status : Approved FDF

                            Sponsor : Scilex Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth